top of page
.png)
All Posts
Why Payers Hold the Key to Your Medtech Launch
For medtech startups, a successful launch hinges on more than innovative technology or regulatory approval—payers are the gatekeepers who...
Karen Nisperos
May 63 min read
4
0
Crafting a Winning Investor Deck: Lessons from the Trenches
Securing funding is a make-or-break moment for biotech startups, where a compelling investor deck can mean the difference between fueling...
Karen Nisperos
May 64 min read
4
0
5 Common GTM Mistakes Biotech Startups Make (And How to Avoid Them)
Launching a biotech startup is a high-stakes endeavor, with innovative therapies facing complex paths to market. A robust go-to-market (GTM) strategy is essential to turn clinical promise into commercial success, yet early-stage life sciences companies often stumble. With 30 years of commercialization expertise in biopharma and medtech, we’ve pinpointed five common GTM mistakes biotech startups make—and how to avoid them to accelerate your market entry.
Karen Nisperos
May 64 min read
3
0
bottom of page